Teva Pharmaceuticals (NYSE: TEVA) beat Q2 earnings estimates, but fell short of Street’s revenue targets. The drug manufacturer reported adjusted EPS of $0.53 on revenue of $3.87 billion for the second quarter of 2020. Teva also confirmed its full-year 2020 outlook. TEVA stock was trading up about 3% in the pre-market trading hours.
For fiscal 2020, the company reaffirmed its previously announced outlook. Revenues are expected to be between $16.6 billion and $17 billion and EPS is forecast to be between $2.30 and $2.55 for FY20.
Revenues slipped 7% year-over-year due to lower revenues from generics, OTC and COPAXONE in all regions and lower revenues from QVAR and BENDEKA/TREANDA in North America segment. Also, demand reduced for certain Teva products, resulting from the impact the COVID-19 pandemic had on purchasing patterns.
“During the quarter, we experienced lower sales of our generic and OTC products in all regions. The lower generics and OTC sales in Europe and International Markets were in line with our expectations, after the unusually high demand seen in the prior quarter due to the initial response to the pandemic,” said CEO Kare Schultz.
Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a
PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the
With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,